Please login to the form below

Not currently logged in
Email:
Password:

HyQvia

This page shows the latest HyQvia news and features for those working in and with pharma, biotech and healthcare.

Shire makes shock $30bn bid for Baxalta

Shire makes shock $30bn bid for Baxalta

The new crop of products that Baxalta is banking on - and which Shire wants to gain access - include primary immunodeficiency therapy HyQvia, launched in the US last October, and long-acting

Latest news

  • Baxalta will add $2.5bn in new product turnover by 2020 Baxalta will add $2.5bn in new product turnover by 2020

    The new crop of products that Baxalta is banking on include primary immunodeficiency therapy HyQvia, launched in the US last October, and long-acting haemophilia A therapy BAX 855 which is

  • Baxter to launch HyQvia in US next week Baxter to launch HyQvia in US next week

    Baxter has confirmed it will launch its HyQvia replacement therapy for primary immunodeficiency (PID) in the US next week, more than a year after it was first introduced in Europe. ... HyQvia was initially turned down by the FDA, which wanted more

  • Baxter re-files HyQvia for immunodeficiency in US Baxter re-files HyQvia for immunodeficiency in US

    Now, Baxter says it has filed everything the regulator asked for and hopes that HyQvia will be approved within the next six months. ... convenience of HyqVia could allow it to capture sales of $1.5bn at peak.

  • EU recommendations for Gilead, Ariad and Baxter drugs EU recommendations for Gilead, Ariad and Baxter drugs

    EMA backs use of HyQvia, Iclusig and Stribild. Gilead Sciences, Ariad Pharma and Baxter have all received backing from the European Medicines Agency (EMA) to market new treatments. ... Baxter's HyQvia is a human normal immunoglobulin that is recommended

More from news
Approximately 4 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals in June 2015 Pharma deals in June 2015

    Roche has two products approved in Europe, Herceptin SC and MabThera SC, and Baxter has HyQvia approved in the US and EU, which utilise the Halozyme approach.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics